255 related articles for article (PubMed ID: 23346096)
1. Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.
Vianna-Jorge R; Festa-Vasconcellos JS; Goulart-Citrangulo SM; Leite MS
Front Genet; 2012; 3():329. PubMed ID: 23346096
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics in breast cancer therapy.
Tan SH; Lee SC; Goh BC; Wong J
Clin Cancer Res; 2008 Dec; 14(24):8027-41. PubMed ID: 19088019
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
7. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
8. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.
de Vries Schultink AH; Zwart W; Linn SC; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2015 Aug; 54(8):797-810. PubMed ID: 25940823
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of anti-estrogen treatment of breast cancer.
Del Re M; Michelucci A; Simi P; Danesi R
Cancer Treat Rev; 2012 Aug; 38(5):442-50. PubMed ID: 21917382
[TBL] [Abstract][Full Text] [Related]
10. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.
Kiyotani K; Mushiroda T; Nakamura Y; Zembutsu H
Drug Metab Pharmacokinet; 2012; 27(1):122-31. PubMed ID: 22041137
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms.
Reis SS; Carvalho AS; Fernandes R
Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31284530
[TBL] [Abstract][Full Text] [Related]
13. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.
Ahern TP; Christensen M; Cronin-Fenton DP; Lunetta KL; Søiland H; Gjerde J; Garne JP; Rosenberg CL; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1937-43. PubMed ID: 21750172
[TBL] [Abstract][Full Text] [Related]
14. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
16. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
Kiyotani K; Mushiroda T; Imamura CK; Hosono N; Tsunoda T; Kubo M; Tanigawara Y; Flockhart DA; Desta Z; Skaar TC; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
J Clin Oncol; 2010 Mar; 28(8):1287-93. PubMed ID: 20124171
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.
Higgins MJ; Stearns V
Curr Oncol Rep; 2010 Jan; 12(1):7-15. PubMed ID: 20425602
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia.
Krajinovic M; Labuda D; Mathonnet G; Labuda M; Moghrabi A; Champagne J; Sinnett D
Clin Cancer Res; 2002 Mar; 8(3):802-10. PubMed ID: 11895912
[TBL] [Abstract][Full Text] [Related]
20. Genomics and pharmacogenomics of breast cancer: current knowledge and trends.
Ayoub N; Lucas C; Kaddoumi A
Asian Pac J Cancer Prev; 2011; 12(5):1127-40. PubMed ID: 21875255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
